Mölndal-based Amferia, a Swedish medtech company specializing in antimicrobial healthcare solutions, has successfully raised €1.2 million in an oversubscribed investment round. The round saw participation from existing investors, new backers, and Chalmers Ventures.
Amferia’s first product, a wound dressing designed for animal health, uses its proprietary hydrogel technology to treat wounds and prevent infections, even those resistant to antibiotics. The new funding will support Amferia’s efforts to expand its product line to include solutions for human health, aiming to address the growing threat of resistant bacterial infections.
Advertisement
Utilizing Antimicrobial Peptides
Amferia’s innovative hydrogel platform stabilizes antimicrobial peptides, which are effective in killing bacteria by puncturing their membranes. This technology mimics the immune system’s natural defenses, offering a safer and more stable alternative to antibiotics. The hydrogel is designed to ensure prolonged antimicrobial action without harming surrounding tissue, making it suitable for a wide range of medical applications.
Strategic Growth and Industry Impact
The funding will also help the company advance clinical trials and secure regulatory approvals, including CE marking and FDA clearance, for its human health products. The company’s technology is being explored for use in sprays for deep wounds, implant coatings, and various catheters, all aimed at improving infection control and patient outcomes.
Expanding Partnerships and Market Presence
In addition to the recent funding, Amferia has signed commercial agreements with Orkla Wound Care and Swiss animal health leader Biokema SA to bring its wound care technology to veterinary markets. The company is also collaborating with Medspray to develop an advanced antimicrobial spray, further expanding its impact on global healthcare.
